BRD4 is believed to be a promising anti-cancer drug target due to its strong positive effects on the expression of the transcription factor MYC, which is a well-known oncogenic master regulator and a driver of colon tumorigenesis (Dhanasekaran et al., 2022). The gene discussed is MYC; the disease is cancer.